TP53 and hepatocellular carcinoma: We also tested the efficacy of aldometanib on another HCC model in which Trp53 is knocked out and Myc is overexpressed, two of the most frequently altered genes in HCC patients, in the mouse liver (MYC;Trp53−/− HCC39).